Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A susceptibility or predisposition to MIRAGE syndrome and monosomy 7 myelodysplasia and leukemia syndrome 2, in which the cause of the disease is a mutation in the SAMD9 gene.
No clinical trials have been registered for SAMD9-related spectrum and myeloid neoplasm risk.
3 publications have been identified in PubMed for SAMD9-related spectrum and myeloid neoplasm risk. Research spans Review / Meta-Analysis (67%) and Epidemiology / Natural History (33%).
Yilmaz Tekinhatun H (2025). [PMID: 41071379](https://pubmed.ncbi.nlm.nih.gov/41071379/). *Immunologic research*. [Epidemiology / Natural History]
Kotmayer L (2025). [PMID: 40568716](https://pubmed.ncbi.nlm.nih.gov/40568716/). *Haematologica*. [Review / Meta-Analysis]
Maese LD (2024). [PMID: 39078402](https://pubmed.ncbi.nlm.nih.gov/39078402/). *Clinical cancer research : an official journal of the American Association for Cancer Research*. [Review / Meta-Analysis]
Data assembled from 2 of 12 sources · Last updated Sep 20, 2026, 8:45 AM UTC
Common questions about SAMD9-related spectrum and myeloid neoplasm risk